Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y606
UPID:
PUS1_HUMAN
Alternative names:
tRNA pseudouridine synthase 1; tRNA pseudouridine(38-40) synthase; tRNA pseudouridylate synthase I; tRNA-uridine isomerase I
Alternative UPACC:
Q9Y606; A8K877; B3KQC1; Q8WYT2; Q9BU44
Background:
Pseudouridylate synthase 1 homolog, known alternatively as tRNA pseudouridine synthase 1, plays a crucial role in the pseudouridylation of tRNAs and mRNAs, impacting positions in the anticodon stem and intron-containing tRNA. This enzyme's activity extends to mRNA, targeting sequences for pseudouridylation that influence mRNA splicing and 3'-end processing, and it regulates nuclear receptor activity via SRA1 mRNA pseudouridylation.
Therapeutic significance:
Linked to Myopathy with lactic acidosis and sideroblastic anemia 1, a rare disorder affecting skeletal muscle and bone marrow, understanding the role of Pseudouridylate synthase 1 homolog could open doors to potential therapeutic strategies.